Low Treg frequency, high CD8+ T-cell frequency, high CD4+ T-cell frequency, and high CD8+ T/Treg ratio can be used as predictors for pancreatic cancer patients treated with neoadjuvant chemotherapy (66, 67). Here, CD8A is linked to pancreatic neoplasm.